publication date: Oct. 20, 2016

Head and Neck Carcinoma Opdivo Stabilized Patient-Reported Outcomes in Phase III Study

In addition, Opdivo more than doubled the time to deterioration for most functional domains measured and significantly delayed the time to worsening symptoms of fatigue, dyspnea and insomnia, compared to investigator’s choice of therapy, the company said.

These findings were presented Oct. 9, during a Presidential Symposium at the 2016 European Society for Medical Oncology Congress and were will be simultaneously published in The New England Journal of Medicine.

“Patients living with this form of advanced head and neck cancer often experience debilitating physiological effects as well as emotional and social challenges brought on by the condition despite current treatment options,” said Kevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London, and a consultant clinical oncologist at the Royal Marsden NHS Foundation Trust in London. “These patient-reported outcomes are encouraging, as they help us understand the potential for Opdivo to impact important quality-of-life measures for this patient population.”

CheckMate -141 is a phase III, open-label, randomized trial that evaluated Opdivo versus investigator’s choice of therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck with tumor progression within six months of platinum therapy in the adjuvant, primary, recurrent or metastatic setting.

Patient-reported outcomes data were collected using the European Organization … Continue reading CCL Oct 2016 – Opdivo Stabilized Patient-Reported Outcomes in Phase III Study

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.